Compare KMPR & IMCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | KMPR | IMCR |
|---|---|---|
| Founded | 1990 | 2008 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Property-Casualty Insurers | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.7B | 1.5B |
| IPO Year | 1995 | 2016 |
| Metric | KMPR | IMCR |
|---|---|---|
| Price | $34.15 | $29.87 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 6 | 12 |
| Target Price | $37.33 | ★ $59.40 |
| AVG Volume (30 Days) | ★ 809.0K | 524.6K |
| Earning Date | 11-09-2026 | 11-06-2026 |
| Dividend Yield | ★ 3.73% | N/A |
| EPS Growth | N/A | ★ 30.39 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $4,789,700,000.00 | $249,428,000.00 |
| Revenue This Year | N/A | $9.30 |
| Revenue Next Year | N/A | $10.23 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | 3.26 | ★ 43.05 |
| 52 Week Low | $22.69 | $27.50 |
| 52 Week High | $41.74 | $40.71 |
| Indicator | KMPR | IMCR |
|---|---|---|
| Relative Strength Index (RSI) | 61.76 | 45.65 |
| Support Level | $28.62 | $27.91 |
| Resistance Level | $34.64 | $31.11 |
| Average True Range (ATR) | 1.52 | 1.50 |
| MACD | 0.02 | 0.04 |
| Stochastic Oscillator | 68.55 | 39.13 |
Kemper Corp is an insurance holding company that offers complementary insurance products through its subsidiaries, including personal and commercial automobile insurance to consumers in targeted markets and industries. Kemper also offers life and other insurance solutions based on the needs of its clients. The company offers its insurance products through a vast network of agents and brokers, mainly under the Kemper Auto and Kemper Life brands. It has two operating segments: Specialty Property & Casualty Insurance and Life Insurance. The majority of the company's revenue is generated from the Specialty Property & Casualty Insurance segment, whose principal products are specialty personal automobile and commercial automobile insurance. Geographically, it operates only in the United States.
Immunocore Holdings PLC is a commercial-stage biotechnology company. Using its ImmTAX platform, the company is developing a deep pipeline in multiple therapeutic areas, including clinical stage programs in oncology and infectious disease, pre-clinical programs in autoimmune disease, and earlier pre-clinical programs across three therapeutic areas. The company's main product, KIMMTRAK, is used for the treatment of unresectable or metastatic uveal melanoma (mUM). The other drug candidates in its pipeline include Brenetafusp, IMC-P115C, IMC-T119C, IMC-R117C, IMC-S118AI, IMC-U120AI, and others, being developed as a potential treatment for various oncology, infectious, and autoimmune diseases.